Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized Double-Blind, 2-Part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-Small Cell Lung Cancer After Failure of First-Line Platinum-Based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.

Next Previous
Trial Profile

A Phase II, Randomized Double-Blind, 2-Part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-Small Cell Lung Cancer After Failure of First-Line Platinum-Based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genzyme Corporation

    • Most Recent Events

    • 08 Apr 2009 Primary outcome amended as reported by ClinicalTrials.gov record (NCT00059722).
    • 08 Apr 2009 Primary outcome amended as reported by ClinicalTrials.gov record (NCT00059722).
    • 08 Apr 2009 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov record (NCT00059722).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top